Trial Title:
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
NCT ID:
NCT05564390
Condition:
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Conditions: Official terms:
Myelodysplastic Syndromes
Cytarabine
Azacitidine
Decitabine
Decitabine and cedazuridine drug combination
Venetoclax
Daunorubicin
Gilteritinib
Study type:
Interventional
Study phase:
Phase 2
Overall status:
Recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Screening
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
Azacitidine
Description:
Given IV or SC
Arm group label:
MM1OA-EA02 Regimen 1 (azacitidine, venetoclax)
Arm group label:
MM1OA-EA02 Regimen 2 (azacitidine, venetoclax, gilteritinib)
Arm group label:
MM1OA-EA02 Regimen 3 (azacitidine, venetoclax, gilteritinib)
Arm group label:
MM1YA-CTG01 Arm II (azacitidine, venetoclax)
Arm group label:
MM1YA-S01 Arm III (azacitidine, venetoclax)
Arm group label:
MM2YA-EA01 Arm D (azacitidine, venetoclax)
Other name:
5 AZC
Other name:
5-AC
Other name:
5-Azacitidine
Other name:
5-Azacytidine
Other name:
5-AZC
Other name:
Azacytidine
Other name:
Azacytidine, 5-
Other name:
Ladakamycin
Other name:
Mylosar
Other name:
U-18496
Other name:
Vidaza
Intervention type:
Other
Intervention name:
Best Practice
Description:
Receive SOC treatment
Arm group label:
TAP (SOC treatment, mutation carrier screening)
Other name:
standard of care
Other name:
standard therapy
Intervention type:
Procedure
Intervention name:
Biopsy
Description:
Undergo biopsy
Arm group label:
MM1OA-EA02 Regimen 1 (azacitidine, venetoclax)
Arm group label:
MM1OA-EA02 Regimen 2 (azacitidine, venetoclax, gilteritinib)
Arm group label:
MM1OA-EA02 Regimen 3 (azacitidine, venetoclax, gilteritinib)
Arm group label:
MM2YA-EA01 Arm A (cytarabine)
Arm group label:
MM2YA-EA01 Arm B (cytarabine, venetoclax)
Arm group label:
MM2YA-EA01 Arm C (Vyxeos, venetoclax)
Arm group label:
MM2YA-EA01 Arm D (azacitidine, venetoclax)
Other name:
BIOPSY_TYPE
Other name:
Bx
Intervention type:
Procedure
Intervention name:
Biospecimen Collection
Description:
Undergo collection of blood samples
Arm group label:
MM1MDS-A01 Arm A (ASTX727)
Arm group label:
MM1MDS-A01 Arm B (ASTX727, enasidenib)
Arm group label:
MM1OA-EA02 Regimen 1 (azacitidine, venetoclax)
Arm group label:
MM1OA-EA02 Regimen 2 (azacitidine, venetoclax, gilteritinib)
Arm group label:
MM1OA-EA02 Regimen 3 (azacitidine, venetoclax, gilteritinib)
Arm group label:
MM1OA-S03 Arm 1 (ASTX727, venetoclax)
Arm group label:
MM1OA-S03 Arm 2 (ASTX727, venetoclax, enasidenib)
Arm group label:
MM1YA-CTG01 Arm I (daunorubicin, cytarabine, venetoclax)
Arm group label:
MM1YA-CTG01 Arm II (azacitidine, venetoclax)
Arm group label:
MM1YA-CTG01 Arm III (daunorubicin, cytarabine)
Arm group label:
MM1YA-S01 Arm I (cytarabine, daunorubicin)
Arm group label:
MM1YA-S01 Arm II (cytarabine, daunorubicin, venetoclax)
Arm group label:
MM1YA-S01 Arm III (azacitidine, venetoclax)
Arm group label:
MM1YA-S01 Arm IV (Vyxeos)
Arm group label:
MM1YA-S01 Arm V (Vyxeos, venetoclax)
Other name:
Biological Sample Collection
Other name:
Biospecimen Collected
Other name:
Specimen Collection
Intervention type:
Procedure
Intervention name:
Biospecimen Collection
Description:
Undergo buccal swab collection
Arm group label:
MM1MDS-A01 Arm A (ASTX727)
Arm group label:
MM1MDS-A01 Arm B (ASTX727, enasidenib)
Other name:
Biological Sample Collection
Other name:
Biospecimen Collected
Other name:
Specimen Collection
Intervention type:
Procedure
Intervention name:
Bone Marrow Aspiration
Description:
Undergo bone marrow aspiration
Arm group label:
MM1MDS-A01 Arm A (ASTX727)
Arm group label:
MM1MDS-A01 Arm B (ASTX727, enasidenib)
Arm group label:
MM1OA-S03 Arm 1 (ASTX727, venetoclax)
Arm group label:
MM1OA-S03 Arm 2 (ASTX727, venetoclax, enasidenib)
Arm group label:
MM1YA-CTG01 Arm I (daunorubicin, cytarabine, venetoclax)
Arm group label:
MM1YA-CTG01 Arm II (azacitidine, venetoclax)
Arm group label:
MM1YA-CTG01 Arm III (daunorubicin, cytarabine)
Arm group label:
MM1YA-S01 Arm I (cytarabine, daunorubicin)
Arm group label:
MM1YA-S01 Arm II (cytarabine, daunorubicin, venetoclax)
Arm group label:
MM1YA-S01 Arm III (azacitidine, venetoclax)
Arm group label:
MM1YA-S01 Arm IV (Vyxeos)
Arm group label:
MM1YA-S01 Arm V (Vyxeos, venetoclax)
Intervention type:
Procedure
Intervention name:
Bone Marrow Biopsy
Description:
Undergo bone marrow biopsy
Arm group label:
MM1OA-S03 Arm 1 (ASTX727, venetoclax)
Arm group label:
MM1OA-S03 Arm 2 (ASTX727, venetoclax, enasidenib)
Other name:
Biopsy of Bone Marrow
Other name:
Biopsy, Bone Marrow
Intervention type:
Drug
Intervention name:
Cytarabine
Description:
Given
Arm group label:
MM1YA-CTG01 Arm I (daunorubicin, cytarabine, venetoclax)
Arm group label:
MM1YA-CTG01 Arm III (daunorubicin, cytarabine)
Arm group label:
MM1YA-S01 Arm I (cytarabine, daunorubicin)
Arm group label:
MM1YA-S01 Arm II (cytarabine, daunorubicin, venetoclax)
Arm group label:
MM2YA-EA01 Arm A (cytarabine)
Arm group label:
MM2YA-EA01 Arm B (cytarabine, venetoclax)
Other name:
.beta.-Cytosine arabinoside
Other name:
1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
Other name:
1-.beta.-D-Arabinofuranosylcytosine
Other name:
1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone
Other name:
1-Beta-D-arabinofuranosylcytosine
Other name:
1.beta.-D-Arabinofuranosylcytosine
Other name:
2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-
Other name:
2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-
Other name:
Alexan
Other name:
Ara-C
Other name:
ARA-cell
Other name:
Arabine
Other name:
Arabinofuranosylcytosine
Other name:
Arabinosylcytosine
Other name:
Aracytidine
Other name:
Aracytin
Other name:
Aracytine
Other name:
Beta-Cytosine Arabinoside
Other name:
CHX-3311
Other name:
Cytarabinum
Other name:
Cytarbel
Other name:
Cytosar
Other name:
Cytosine Arabinoside
Other name:
Cytosine-.beta.-arabinoside
Other name:
Cytosine-beta-arabinoside
Other name:
Erpalfa
Other name:
Starasid
Other name:
Tarabine PFS
Other name:
U 19920
Other name:
U-19920
Other name:
Udicil
Other name:
WR-28453
Intervention type:
Drug
Intervention name:
Daunorubicin Hydrochloride
Description:
Given IV
Arm group label:
MM1YA-CTG01 Arm I (daunorubicin, cytarabine, venetoclax)
Arm group label:
MM1YA-CTG01 Arm III (daunorubicin, cytarabine)
Arm group label:
MM1YA-S01 Arm I (cytarabine, daunorubicin)
Arm group label:
MM1YA-S01 Arm II (cytarabine, daunorubicin, venetoclax)
Other name:
Cerubidin
Other name:
Cerubidine
Other name:
Cloridrato de Daunorubicina
Other name:
Daunoblastin
Other name:
Daunoblastina
Other name:
Daunoblastine
Other name:
Daunomycin Hydrochloride
Other name:
Daunomycin, hydrochloride
Other name:
Daunorubicin.HCl
Other name:
Daunorubicini Hydrochloridum
Other name:
FI-6339
Other name:
Ondena
Other name:
RP-13057
Other name:
Rubidomycin Hydrochloride
Other name:
Rubilem
Intervention type:
Drug
Intervention name:
Decitabine and Cedazuridine
Description:
Given PO
Arm group label:
MM1MDS-A01 Arm A (ASTX727)
Arm group label:
MM1MDS-A01 Arm B (ASTX727, enasidenib)
Arm group label:
MM1OA-S03 Arm 1 (ASTX727, venetoclax)
Arm group label:
MM1OA-S03 Arm 2 (ASTX727, venetoclax, enasidenib)
Other name:
ASTX 727
Other name:
ASTX-727
Other name:
ASTX727
Other name:
C-DEC
Other name:
CDA Inhibitor E7727/Decitabine Combination Agent ASTX727
Other name:
Cedazuridine/Decitabine Combination Agent ASTX727
Other name:
Cedazuridine/Decitabine Tablet
Other name:
DEC-C
Other name:
Inaqovi
Other name:
Inqovi
Intervention type:
Procedure
Intervention name:
Echocardiography
Description:
Undergo ECHO
Arm group label:
MM1YA-S01 Arm I (cytarabine, daunorubicin)
Arm group label:
MM1YA-S01 Arm II (cytarabine, daunorubicin, venetoclax)
Arm group label:
MM1YA-S01 Arm III (azacitidine, venetoclax)
Arm group label:
MM1YA-S01 Arm IV (Vyxeos)
Arm group label:
MM1YA-S01 Arm V (Vyxeos, venetoclax)
Arm group label:
MM2YA-EA01 Arm A (cytarabine)
Arm group label:
MM2YA-EA01 Arm B (cytarabine, venetoclax)
Arm group label:
MM2YA-EA01 Arm C (Vyxeos, venetoclax)
Arm group label:
MM2YA-EA01 Arm D (azacitidine, venetoclax)
Other name:
EC
Intervention type:
Drug
Intervention name:
Enasidenib
Description:
Given PO
Arm group label:
MM1MDS-A01 Arm B (ASTX727, enasidenib)
Arm group label:
MM1OA-S03 Arm 2 (ASTX727, venetoclax, enasidenib)
Other name:
AG 221
Other name:
AG-221
Other name:
AG221
Other name:
CC-90007 Free Base
Intervention type:
Drug
Intervention name:
Gilteritinib
Description:
Given PO
Arm group label:
MM1OA-EA02 Regimen 2 (azacitidine, venetoclax, gilteritinib)
Arm group label:
MM1OA-EA02 Regimen 3 (azacitidine, venetoclax, gilteritinib)
Other name:
ASP 2215
Other name:
ASP-2215
Other name:
ASP2215
Intervention type:
Drug
Intervention name:
Liposome-encapsulated Daunorubicin-Cytarabine
Description:
Given IV
Arm group label:
MM1YA-S01 Arm IV (Vyxeos)
Arm group label:
MM1YA-S01 Arm V (Vyxeos, venetoclax)
Arm group label:
MM2YA-EA01 Arm C (Vyxeos, venetoclax)
Other name:
CPX 351
Other name:
CPX-351
Other name:
CPX351
Other name:
Cytarabine and Daunorubicin Liposomal
Other name:
Cytarabine-Daunorubicin Liposome for Injection
Other name:
Daunorubicin and Cytarabine (Liposomal)
Other name:
Liposomal AraC-Daunorubicin CPX-351
Other name:
Liposomal Cytarabine-Daunorubicin
Other name:
Liposome-encapsulated Combination of Daunorubicin and Cytarabine
Other name:
Vyxeos
Intervention type:
Procedure
Intervention name:
Multigated Acquisition Scan
Description:
Undergo MUGA
Arm group label:
MM1YA-S01 Arm I (cytarabine, daunorubicin)
Arm group label:
MM1YA-S01 Arm II (cytarabine, daunorubicin, venetoclax)
Arm group label:
MM1YA-S01 Arm III (azacitidine, venetoclax)
Arm group label:
MM1YA-S01 Arm IV (Vyxeos)
Arm group label:
MM1YA-S01 Arm V (Vyxeos, venetoclax)
Arm group label:
MM2YA-EA01 Arm A (cytarabine)
Arm group label:
MM2YA-EA01 Arm B (cytarabine, venetoclax)
Arm group label:
MM2YA-EA01 Arm C (Vyxeos, venetoclax)
Arm group label:
MM2YA-EA01 Arm D (azacitidine, venetoclax)
Other name:
Blood Pool Scan
Other name:
Equilibrium Radionuclide Angiography
Other name:
Gated Blood Pool Imaging
Other name:
Gated Heart Pool Scan
Other name:
MUGA
Other name:
MUGA Scan
Other name:
Multi-Gated Acquisition Scan
Other name:
Radionuclide Ventriculogram Scan
Other name:
Radionuclide Ventriculography
Other name:
RNV Scan
Other name:
RNVG
Other name:
SYMA Scanning
Other name:
Synchronized Multigated Acquisition Scanning
Intervention type:
Procedure
Intervention name:
Mutation Carrier Screening
Description:
Undergo rapid genetic testing
Arm group label:
Screening (mutation carrier screening)
Arm group label:
TAP (SOC treatment, mutation carrier screening)
Intervention type:
Drug
Intervention name:
Venetoclax
Description:
Given PO
Arm group label:
MM1OA-EA02 Regimen 1 (azacitidine, venetoclax)
Arm group label:
MM1OA-EA02 Regimen 2 (azacitidine, venetoclax, gilteritinib)
Arm group label:
MM1OA-EA02 Regimen 3 (azacitidine, venetoclax, gilteritinib)
Arm group label:
MM1OA-S03 Arm 1 (ASTX727, venetoclax)
Arm group label:
MM1OA-S03 Arm 2 (ASTX727, venetoclax, enasidenib)
Arm group label:
MM1YA-CTG01 Arm I (daunorubicin, cytarabine, venetoclax)
Arm group label:
MM1YA-CTG01 Arm II (azacitidine, venetoclax)
Arm group label:
MM1YA-S01 Arm II (cytarabine, daunorubicin, venetoclax)
Arm group label:
MM1YA-S01 Arm III (azacitidine, venetoclax)
Arm group label:
MM1YA-S01 Arm V (Vyxeos, venetoclax)
Arm group label:
MM2YA-EA01 Arm B (cytarabine, venetoclax)
Arm group label:
MM2YA-EA01 Arm C (Vyxeos, venetoclax)
Arm group label:
MM2YA-EA01 Arm D (azacitidine, venetoclax)
Other name:
ABT 199
Other name:
ABT-0199
Other name:
ABT-199
Other name:
ABT199
Other name:
GDC 0199
Other name:
GDC-0199
Other name:
GDC0199
Other name:
RG7601
Other name:
Venclexta
Other name:
Venclyxto
Summary:
This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a
screening tool and specific laboratory tests to help improve participants' ability to
register to clinical trials throughout the course of their myeloid cancer (acute myeloid
leukemia or myelodysplastic syndrome) treatment. This study involves testing patients'
bone marrow and blood for certain biomarkers. A biomarker (sometimes called a marker) is
any molecule in the body that can be measured. Doctors look at markers to learn what is
happening in the body. Knowing about certain markers can give doctors more information
about what is driving the cancer and how to treat it. Testing patients' bone marrow and
blood will show doctors if patients have markers that specific drugs can target. The
marker testing in this study will let doctors know if they can match patients with a
treatment study (myeloMATCH clinical trial) that tests treatment for the type of cancer
they have or continue standard of care treatment with their doctor on the Tier
Advancement Pathway (TAP).
Detailed description:
PRIMARY OBJECTIVES:
I. Screening and Reassessment (MSRP): To evaluate the feasibility of MATCHBox receiving
and organizing all data needed for assignment to a myeloMATCH clinical trial or Tier
Advancement Pathway (TAP) within 72 hours of MDNet receipt of all required specimens for
initial therapy and within 10 days for subsequent therapy.
II. Tier Advancement Pathway (TAP): To enable participants who are not matched to an
investigational myeloMATCH treatment substudy to receive standard of care (SOC) while
remaining on the MSRP to maintain access to later tiers of treatment substudies.
SECONDARY OBJECTIVES:
I. Screening and Reassessment (MSRP):
Ia. To describe the time to generation of all data required for treatment substudy (or
TAP) assignment, time to treatment substudy (or TAP) assignment, percent assigned to a
myeloMATCH treatment substudy, and the percent of screened participants who register to a
myeloMATCH investigational treatment substudy or are assigned to TAP:
Iai. Separately within each tier of myeloMATCH treatment substudy and analogous TAP
assignment; Ibi. Separately within each clinical basket of myeloMATCH treatment
substudies; Ici. Over time, across and within the categories above.
II. Tier Advancement Pathway (TAP):
IIa. To evaluate participants for assignment to higher tier treatment substudies within
myeloMATCH; IIb. To describe, within tier- and basket- levels of TAP, measurable residual
disease (MRD) rates and clonal evolution; IIc. To describe, within tier- and basket-
levels of TAP, remission status and overall survival of participants who receive standard
of care therapy; IId. To obtain MDNet specimens for translational medicine and
biobanking.
OUTLINE:
REGISTRATION: Patients undergo bone marrow aspiration and collection of blood on study.
Patients' bone marrow and blood specimens undergo rapid genetic testing. Patients are
then assigned to a specific substudy containing a therapy targeted to the patient's
mutational profile. If there is no targetable mutation, the patient is placed on a
substudy testing novel combinations that do not contain a target-specific drug. Patients
who are not eligible for any MYELOMATCH substudy are assigned to TAP.
TAP: Patients continue SOC treatment and undergo continued bone marrow aspiration and
blood collection for possible future substudy assignment.
TREATMENT: Patients are assigned to a specific treatment substudy.
MM1YA-CTG01: Younger patients (age 18-59 years) with intermediate risk acute myeloid
leukemia (AML) are randomized to 1 of 3 arms.
ARM I: Patients receive daunorubicin intravenously (IV), cytarabine IV, and venetoclax
orally (PO) on study and undergo bone marrow aspiration and collection of blood samples
on study and as clinically indicated.
ARM II: Patients receive azacitidine IV or subcutaneously (SC) and venetoclax PO on study
and undergo bone marrow aspiration and collection of blood samples on study and as
clinically indicated.
ARM III: Patients receive daunorubicin IV and cytarabine IV on study and undergo bone
marrow aspiration and collection of blood samples on study and as clinically indicated.
MM1YA-S01: Younger patients (age 18-59 years) with high-risk AML are randomized to 1 of 5
arms.
ARM I: Patients receive cytarabine IV continuously on days 1-7 and daunorubicin IV on
days 1-3 per standard approach of each cycle. Cycles repeat every 28 days for 1 cycle in
the absence of disease progression or unacceptable toxicity. Patients may receive an
additional cycle of cytarabine IV continuously on days 1-5 and daunorubicin IV on days
1-2. Patients undergo echocardiography (ECHO) or multigated acquisition (MUGA) scan
during screening. Patients also undergo a bone marrow aspiration and collection of blood
throughout the trial.
ARM II: Patients receive cytarabine IV continuously on days 2-8 and daunorubicin IV on
days 2-4 with venetoclax PO on days 1-11 of each cycle. Cycles repeat every 28 days for 1
cycle in the absence of disease progression or unacceptable toxicity. Patients may
receive an additional cycle of cytarabine IV continuously on days 2-6 and daunorubicin IV
on days 2-3 with venetoclax PO on days 1-8. Patients undergo ECHO or MUGA scan during
screening. Patients also undergo a bone marrow aspiration and collection of blood
throughout the trial.
ARM III: Patients receive azacitidine SC or IV on days 1-7 and venetoclax PO on days 1-28
of each cycle. Cycles repeat every 28 days for 2 cycles in the absence of disease
progression or unacceptable toxicity. Patients undergo ECHO or MUGA scan during
screening. Patients also undergo a bone marrow aspiration and collection of blood
throughout the trial.
ARM IV: Patients receive daunorubicin and cytarabine liposome IV over 90 minutes on days
1, 3, and 5 of each cycle. Cycles repeat every 28 days for 1 cycle in the absence of
disease progression or unacceptable toxicity. Patients may receive an additional cycle of
daunorubicin and cytarabine liposome IV over 90 minutes on days 1 and 3. Patients undergo
ECHO or MUGA scan during screening. Patients also undergo a bone marrow aspiration and
collection of blood throughout the trial.
MM2YA-EA01: Younger patients (age 18-59 years) with AML or secondary AML who have
completed a tier 1 MyeloMATCH treatment study with complete remission (CR) or CR with
partial hematologic recovery (CRh) and have detectable minimal residual disease (MRD) (>
0.1%) are randomized to 1 of 4 arms.
ARM A: Patients receive cytarabine IV on study. Patients undergo bone marrow aspiration
and biopsy on study. Patients may also undergo ECHO and/or MUGA as clinically indicated.
ARM B: Patients receive cytarabine IV and venetoclax PO on study. Patients undergo bone
marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as
clinically indicated.
ARM C: Patients receive Vyxeos IV and venetoclax PO on study. Patients undergo bone
marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as
clinically indicated.
ARM D: Patients receive azacitidine IV or SC and venetoclax PO on study. Patients undergo
bone marrow aspiration and biopsy on study. Patients may also undergo ECHO and/or MUGA as
clinically indicated.
MM1OA-EA02: Patients are randomized to 1 of 3 regimens.
REGIMEN 1:
INDUCTION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax PO on days
1-28 of each cycle. Treatment repeats every 28 days for up to 2 cycles or until patient
achieves remission, whichever comes first, in the absence of disease progression or
unacceptable toxicity.
CONSOLIDATION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax PO on
days 1-28 of each cycle. Cycles repeat every 28 days for 2 years in the absence of
disease progression or unacceptable toxicity.
REGIMEN 2:
INDUCTION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax and
gilteritinib PO on days 1-28 of each cycle. Treatment repeats every 28 days for up to 2
cycles or until patient achieves remission, whichever comes first, in the absence of
disease progression or unacceptable toxicity.
CONSOLIDATION: Patients receive azacitidine IV or SC on days 1-5, venetoclax PO on days
1-7 and gilteritinib PO on days 1-28 of each cycle. Cycles repeat every 28 days for 2
years in the absence of disease progression or unacceptable toxicity.
REGIMEN 3:
INDUCTION: Patients receive azacitidine IV or SC on days 1-7 and venetoclax PO on days
1-28, and gilteritinib PO on days 8-21 of each cycle. Treatment repeats every 28 days for
up to 2 cycles or until patient achieves remission, whichever comes first, in the absence
of disease progression or unacceptable toxicity.
CONSOLIDATION: Patients receive azacitidine IV or SC on days 1-5, venetoclax PO on days
1-14 and gilteritinib PO on days 8-21 of each cycle. Cycles repeat every 28 days for 2
years in the absence of disease progression or unacceptable toxicity.
MM1MDS-A01: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive ASTX727 PO once daily (QD) on days 1-5 of each cycle. Cycles
repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Patients who do not achieve a CR, CRL, or CRh at the end of cycle 6 may cross-over to Arm
B. Patients who experience CR, PR, or stable disease (SD) any time after 4 cycles of
treatment may be reassessed in order to go to a higher myeloMATCH tier assignment or to
TAP. Patients also undergo bone marrow biopsy and aspiration throughout the study.
Patients may also undergo optional buccal swab on study, and/or optional additional bone
marrow aspiration and blood sample collection on study and at disease progression.
ARM B: Patients receive ASTX727 PO QD on days 1-5 and enasidenib PO QD on days 1-28 of
each cycle. Cycles repeat every 28 days in the absence of disease progression or
unacceptable toxicity. Patients who experience CR, PR, or SD any time after 4 cycles of
treatment may be reassessed in order to go to a higher myeloMATCH tier assignment or to
TAP. Patients also undergo bone marrow biopsy and aspiration throughout the study.
Patients may also undergo optional buccal swab on study, and/or optional additional bone
marrow aspiration and blood sample collection on study and at disease progression.
MM1OA-S03: Patients are randomized to 1 of 2 arms.
ARM 1: Patients receive ASTX727 PO QD on days 1-5 and venetoclax PO QD on days 1-28 of
each cycle. Cycles repeat every 28 days in the absence of disease progression or
unacceptable toxicity. Patients also undergo blood sample collection, bone marrow
aspiration, and bone marrow biopsy throughout the trial.
ARM 2: Patients receive ASTX727 PO QD on days 1-5, venetoclax PO QD on days 1-28, and
enasidenib PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence
of disease progression or unacceptable toxicity. Patients also undergo blood sample
collection, bone marrow aspiration, and bone marrow biopsy throughout the trial.
All patients undergo bone marrow biopsy and aspiration as well as blood sample collection
on the trial.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Participants must be suspected to have previously untreated acute myeloid leukemia
(AML) or myelodysplastic syndrome (MDS). Participants with AML cannot have a history
of previously treated myeloproliferative neoplasms (MPN) or MDS.
- Participants must be >= 18 years of age.
- Participants must not have received prior anti-cancer therapy for AML or MDS.
- Note: Hydroxyurea to control the white blood cell count (WBC) is allowed.
- Note: Prior erythroid stimulating agent (ESA) is not considered prior therapy
for the purposes of eligibility. Participants must not be currently receiving
any cytarabine-containing therapy other than up to 1 g/m^2 of cytarabine, which
is allowed for urgent cytoreduction.
- Participants are allowed prior use of hydroxyurea, all-trans retinoic acid (ATRA),
BCR-ABL directed tyrosine kinase inhibitor, erythropoiesis-stimulating agent,
thrombopoietin receptor agonist and lenalidomide, with a maximum limit of 1 month of
exposure.
- Note: Participants receiving hydroxyurea prior to treatment substudy or TAP
assignment must agree to discontinue hydroxyurea within 24 hours before
beginning substudy or TAP treatment.
- Participants must not have a prior or concurrent malignancy that requires concurrent
anti-cancer therapy
- Note: active hormonal therapy is allowed
- Participants must have a Zubrod Performance Status evaluation within 28 days prior
to registration.
- Participants must agree to have translational medicine specimens submitted.
- Participants must be offered the opportunity to participate in specimen banking.
- Note: Specimens must be collected and submitted following the initial
paper-based process and subsequently via the Precision Medicine Specimen
Tracking Forms in Medidata Rave instance for the MyeloMATCH MSRP.
- Participants must be informed of the investigational nature of this study and must
sign and give informed consent in accordance with institutional and federal
guidelines.
- Note: As a part of the Oncology Patient Enrollment Network (OPEN) registration
process the treating institution's identity is provided in order to ensure that
the current (within 365 days) date of institutional review board approval for
this study has been entered in the system.
- The master screening and reassessment protocol (MSRP) should only be used in sites
where the relevant AML treatment substudies are open or if the site is willing to
follow the MSRP Tier Advancement Pathway (TAP) for patients in the event that the
site does not have the relevant study open and transfer to another site that does
have the study open. For example, if a site does not have a myeloMATCH Tier 1 study
for older AML open for enrollment, such older AML patients should only be consented
for the MSRP if the site is willing to treat the patient with standard of care on
TAP or is willing to transfer the patient to a center with a study open that the
patient would otherwise match to.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Banner University Medical Center - Tucson
Address:
City:
Tucson
Zip:
85719
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Email:
UACC-IIT@uacc.arizona.edu
Investigator:
Last name:
Sharad Khurana
Email:
Principal Investigator
Facility:
Name:
University of Arizona Cancer Center-North Campus
Address:
City:
Tucson
Zip:
85719
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Email:
UACC-IIT@uacc.arizona.edu
Investigator:
Last name:
Sharad Khurana
Email:
Principal Investigator
Facility:
Name:
Tibor Rubin VA Medical Center
Address:
City:
Long Beach
Zip:
90822
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
562-826-8000
Investigator:
Last name:
Helen Ma
Email:
Principal Investigator
Facility:
Name:
Cedars Sinai Medical Center
Address:
City:
Los Angeles
Zip:
90048
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
310-423-8965
Investigator:
Last name:
Noah M. Merin
Email:
Principal Investigator
Facility:
Name:
Yale University
Address:
City:
New Haven
Zip:
06520
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
203-785-5702
Email:
canceranswers@yale.edu
Investigator:
Last name:
Rory M. Shallis
Email:
Principal Investigator
Facility:
Name:
Veterans Affairs Connecticut Healthcare System-West Haven Campus
Address:
City:
West Haven
Zip:
06516
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
203-937-3421
Phone ext:
2832
Investigator:
Last name:
Alexander Pine
Email:
Principal Investigator
Facility:
Name:
Augusta University Medical Center
Address:
City:
Augusta
Zip:
30912
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
706-721-2388
Email:
ga_cares@augusta.edu
Investigator:
Last name:
Vamsi Kota
Email:
Principal Investigator
Facility:
Name:
Kootenai Health - Coeur d'Alene
Address:
City:
Coeur d'Alene
Zip:
83814
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Kootenai Clinic Cancer Services - Post Falls
Address:
City:
Post Falls
Zip:
83854
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Kootenai Clinic Cancer Services - Sandpoint
Address:
City:
Sandpoint
Zip:
83864
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
OSF Saint Joseph Medical Center
Address:
City:
Bloomington
Zip:
61701
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Bloomington
Address:
City:
Bloomington
Zip:
61704
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Canton
Address:
City:
Canton
Zip:
61520
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Carthage
Address:
City:
Carthage
Zip:
62321
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Northwestern University
Address:
City:
Chicago
Zip:
60611
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
312-695-1301
Email:
cancer@northwestern.edu
Investigator:
Last name:
Jessica K. Altman
Email:
Principal Investigator
Facility:
Name:
University of Chicago Comprehensive Cancer Center
Address:
City:
Chicago
Zip:
60637
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
773-702-8222
Email:
cancerclinicaltrials@bsd.uchicago.edu
Investigator:
Last name:
Olatoyosi M. Odenike
Email:
Principal Investigator
Facility:
Name:
Carle at The Riverfront
Address:
City:
Danville
Zip:
61832
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-446-5532
Email:
Research@Carle.com
Investigator:
Last name:
Suparna Mantha
Email:
Principal Investigator
Facility:
Name:
Cancer Care Specialists of Illinois - Decatur
Address:
City:
Decatur
Zip:
62526
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
217-876-4762
Email:
morganthaler.jodi@mhsil.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Decatur Memorial Hospital
Address:
City:
Decatur
Zip:
62526
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
217-876-4762
Email:
morganthaler.jodi@mhsil.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Northwestern Medicine Cancer Center Kishwaukee
Address:
City:
DeKalb
Zip:
60115
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
630-352-5360
Email:
Donald.Smith3@nm.org
Investigator:
Last name:
Jessica K. Altman
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Dixon
Address:
City:
Dixon
Zip:
61021
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
815-285-7800
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Carle Physician Group-Effingham
Address:
City:
Effingham
Zip:
62401
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-446-5532
Email:
Research@carle.com
Investigator:
Last name:
Suparna Mantha
Email:
Principal Investigator
Facility:
Name:
Crossroads Cancer Center
Address:
City:
Effingham
Zip:
62401
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
217-876-4762
Email:
morganthaler.jodi@mhsil.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Eureka
Address:
City:
Eureka
Zip:
61530
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Galesburg
Address:
City:
Galesburg
Zip:
61401
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Northwestern Medicine Cancer Center Delnor
Address:
City:
Geneva
Zip:
60134
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
630-352-5360
Email:
Donald.Smith3@nm.org
Investigator:
Last name:
Jessica K. Altman
Email:
Principal Investigator
Facility:
Name:
Northwestern Medicine Glenview Outpatient Center
Address:
City:
Glenview
Zip:
60026
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
312-695-1102
Investigator:
Last name:
Jessica K. Altman
Email:
Principal Investigator
Facility:
Name:
Northwestern Medicine Grayslake Outpatient Center
Address:
City:
Grayslake
Zip:
60030
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
312-695-1102
Investigator:
Last name:
Jessica K. Altman
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Kewanee Clinic
Address:
City:
Kewanee
Zip:
61443
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Northwestern Medicine Lake Forest Hospital
Address:
City:
Lake Forest
Zip:
60045
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Email:
cancertrials@northwestern.edu
Investigator:
Last name:
Jessica K. Altman
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Macomb
Address:
City:
Macomb
Zip:
61455
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Carle Physician Group-Mattoon/Charleston
Address:
City:
Mattoon
Zip:
61938
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-446-5532
Email:
Research@carle.com
Investigator:
Last name:
Suparna Mantha
Email:
Principal Investigator
Facility:
Name:
Northwestern Medicine Orland Park
Address:
City:
Orland Park
Zip:
60462
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Email:
nctnprogram_rhlccc@northwestern.edu
Investigator:
Last name:
Jessica K. Altman
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Ottawa Clinic
Address:
City:
Ottawa
Zip:
61350
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Pekin
Address:
City:
Pekin
Zip:
61554
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Peoria
Address:
City:
Peoria
Zip:
61615
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Methodist Medical Center of Illinois
Address:
City:
Peoria
Zip:
61636
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
OSF Saint Francis Medical Center
Address:
City:
Peoria
Zip:
61637
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Peru
Address:
City:
Peru
Zip:
61354
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare-Princeton
Address:
City:
Princeton
Zip:
61356
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Southern Illinois University School of Medicine
Address:
City:
Springfield
Zip:
62702
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
217-545-7929
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Springfield Clinic
Address:
City:
Springfield
Zip:
62702
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-444-7541
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Springfield Memorial Hospital
Address:
City:
Springfield
Zip:
62781
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
217-528-7541
Email:
pallante.beth@mhsil.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Carle Cancer Center
Address:
City:
Urbana
Zip:
61801
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-446-5532
Email:
Research@carle.com
Investigator:
Last name:
Suparna Mantha
Email:
Principal Investigator
Facility:
Name:
Northwestern Medicine Cancer Center Warrenville
Address:
City:
Warrenville
Zip:
60555
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
630-352-5360
Email:
Donald.Smith3@nm.org
Investigator:
Last name:
Jessica K. Altman
Email:
Principal Investigator
Facility:
Name:
Illinois CancerCare - Washington
Address:
City:
Washington
Zip:
61571
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
309-243-3605
Email:
andersonj@illinoiscancercare.com
Investigator:
Last name:
Bryan A. Faller
Email:
Principal Investigator
Facility:
Name:
Indiana University/Melvin and Bren Simon Cancer Center
Address:
City:
Indianapolis
Zip:
46202
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
317-278-5632
Email:
iutrials@iu.edu
Investigator:
Last name:
Rita Assi
Email:
Principal Investigator
Facility:
Name:
Mission Cancer and Blood - West Des Moines
Address:
City:
Clive
Zip:
50325
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
515-241-3305
Investigator:
Last name:
Richard L. Deming
Email:
Principal Investigator
Facility:
Name:
Mercy Medical Center - Des Moines
Address:
City:
Des Moines
Zip:
50314
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
515-358-6613
Email:
cancerresearch@mercydesmoines.org
Investigator:
Last name:
Richard L. Deming
Email:
Principal Investigator
Facility:
Name:
Mission Cancer and Blood - Laurel
Address:
City:
Des Moines
Zip:
50314
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
515-241-3305
Investigator:
Last name:
Richard L. Deming
Email:
Principal Investigator
Facility:
Name:
University of Iowa/Holden Comprehensive Cancer Center
Address:
City:
Iowa City
Zip:
52242
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-237-1225
Investigator:
Last name:
Prajwal Dhakal
Email:
Principal Investigator
Facility:
Name:
University of Kansas Clinical Research Center
Address:
City:
Fairway
Zip:
66205
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
913-588-3671
Email:
KUCC_Navigation@kumc.edu
Investigator:
Last name:
Tara L. Lin
Email:
Principal Investigator
Facility:
Name:
HaysMed
Address:
City:
Hays
Zip:
67601
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
785-623-5774
Investigator:
Last name:
Tara L. Lin
Email:
Principal Investigator
Facility:
Name:
University of Kansas Cancer Center
Address:
City:
Kansas City
Zip:
66160
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
913-588-3671
Email:
KUCC_Navigation@kumc.edu
Investigator:
Last name:
Tara L. Lin
Email:
Principal Investigator
Facility:
Name:
Lawrence Memorial Hospital
Address:
City:
Lawrence
Zip:
66044
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
785-505-2800
Email:
Stephanie.Norris@LMH.ORG
Investigator:
Last name:
Tara L. Lin
Email:
Principal Investigator
Facility:
Name:
Olathe Health Cancer Center
Address:
City:
Olathe
Zip:
66061
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
913-355-3943
Email:
atheCCResearch@kumc.edu
Investigator:
Last name:
Tara L. Lin
Email:
Principal Investigator
Facility:
Name:
University of Kansas Cancer Center-Overland Park
Address:
City:
Overland Park
Zip:
66210
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
913-588-3671
Email:
KUCC_Navigation@kumc.edu
Investigator:
Last name:
Tara L. Lin
Email:
Principal Investigator
Facility:
Name:
University of Kansas Hospital-Indian Creek Campus
Address:
City:
Overland Park
Zip:
66211
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
913-588-3671
Email:
KUCC_Navigation@kumc.edu
Investigator:
Last name:
Tara L. Lin
Email:
Principal Investigator
Facility:
Name:
Salina Regional Health Center
Address:
City:
Salina
Zip:
67401
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
785-452-7038
Email:
mleepers@srhc.com
Investigator:
Last name:
Tara L. Lin
Email:
Principal Investigator
Facility:
Name:
University of Kansas Health System Saint Francis Campus
Address:
City:
Topeka
Zip:
66606
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
785-295-8000
Investigator:
Last name:
Tara L. Lin
Email:
Principal Investigator
Facility:
Name:
University of Kansas Hospital-Westwood Cancer Center
Address:
City:
Westwood
Zip:
66205
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
913-588-3671
Email:
KUCC_Navigation@kumc.edu
Investigator:
Last name:
Tara L. Lin
Email:
Principal Investigator
Facility:
Name:
The James Graham Brown Cancer Center at University of Louisville
Address:
City:
Louisville
Zip:
40202
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
502-562-3429
Investigator:
Last name:
Mohamed M. Hegazi
Email:
Principal Investigator
Facility:
Name:
UofL Health Medical Center Northeast
Address:
City:
Louisville
Zip:
40245
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
502-852-2755
Email:
ctoinfo@louisville.edu
Investigator:
Last name:
Mohamed M. Hegazi
Email:
Principal Investigator
Facility:
Name:
Tufts Medical Center
Address:
City:
Boston
Zip:
02111
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
617-636-5000
Email:
ContactUsCancerCenter@TuftsMedicalCenter.org
Investigator:
Last name:
Andreas K. Klein
Email:
Principal Investigator
Facility:
Name:
Trinity Health Saint Joseph Mercy Hospital Ann Arbor
Address:
City:
Ann Arbor
Zip:
48106
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health IHA Medical Group Hematology Oncology - Brighton
Address:
City:
Brighton
Zip:
48114
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health IHA Medical Group Hematology Oncology - Canton
Address:
City:
Canton
Zip:
48188
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
Address:
City:
Chelsea
Zip:
48118
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Wayne State University/Karmanos Cancer Institute
Address:
City:
Detroit
Zip:
48201
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
313-576-9790
Email:
ctoadmin@karmanos.org
Investigator:
Last name:
Vijendra Singh
Email:
Principal Investigator
Facility:
Name:
Weisberg Cancer Treatment Center
Address:
City:
Farmington Hills
Zip:
48334
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
313-576-9790
Email:
ctoadmin@karmanos.org
Investigator:
Last name:
Vijendra Singh
Email:
Principal Investigator
Facility:
Name:
Genesee Cancer and Blood Disease Treatment Center
Address:
City:
Flint
Zip:
48503
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
810-762-8038
Email:
wstrong@ghci.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Genesee Hematology Oncology PC
Address:
City:
Flint
Zip:
48503
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
810-762-8038
Email:
wstrong@ghci.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Genesys Hurley Cancer Institute
Address:
City:
Flint
Zip:
48503
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
810-762-8038
Email:
wstrong@ghci.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Hurley Medical Center
Address:
City:
Flint
Zip:
48503
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
810-762-8038
Email:
wstrong@ghci.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health Saint Mary Mercy Livonia Hospital
Address:
City:
Livonia
Zip:
48154
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
Address:
City:
Ypsilanti
Zip:
48197
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
734-712-7251
Email:
MCRCwebsitecontactform@stjoeshealth.org
Investigator:
Last name:
Tareq Al baghdadi
Email:
Principal Investigator
Facility:
Name:
Essentia Health - Deer River Clinic
Address:
City:
Deer River
Zip:
56636
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
218-786-3308
Email:
CancerTrials@EssentiaHealth.org
Investigator:
Last name:
Bret E. Friday
Email:
Principal Investigator
Facility:
Name:
Essentia Health Cancer Center
Address:
City:
Duluth
Zip:
55805
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
218-786-3308
Email:
CancerTrials@EssentiaHealth.org
Investigator:
Last name:
Bret E. Friday
Email:
Principal Investigator
Facility:
Name:
Fairview Southdale Hospital
Address:
City:
Edina
Zip:
55435
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
952-993-1517
Email:
mmcorc@healthpartners.com
Investigator:
Last name:
David M. King
Email:
Principal Investigator
Facility:
Name:
Essentia Health Hibbing Clinic
Address:
City:
Hibbing
Zip:
55746
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
218-786-3308
Investigator:
Last name:
Bret E. Friday
Email:
Principal Investigator
Facility:
Name:
Essentia Health Virginia Clinic
Address:
City:
Virginia
Zip:
55792
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
218-786-3308
Email:
CancerTrials@EssentiaHealth.org
Investigator:
Last name:
Bret E. Friday
Email:
Principal Investigator
Facility:
Name:
Baptist Memorial Hospital and Cancer Center-Golden Triangle
Address:
City:
Columbus
Zip:
39705
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
901-226-1366
Email:
BCCclintrials@bmhcc.org
Investigator:
Last name:
Salil Goorha
Email:
Principal Investigator
Facility:
Name:
Baptist Cancer Center-Grenada
Address:
City:
Grenada
Zip:
38901
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
901-226-1366
Email:
BCCclintrials@bmhcc.org
Investigator:
Last name:
Salil Goorha
Email:
Principal Investigator
Facility:
Name:
Baptist Memorial Hospital and Cancer Center-Union County
Address:
City:
New Albany
Zip:
38652
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
901-226-1366
Email:
BCCclintrials@bmhcc.org
Investigator:
Last name:
Salil Goorha
Email:
Principal Investigator
Facility:
Name:
Baptist Memorial Hospital and Cancer Center-Oxford
Address:
City:
Oxford
Zip:
38655
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
901-226-1366
Email:
BCCclintrials@bmhcc.org
Investigator:
Last name:
Salil Goorha
Email:
Principal Investigator
Facility:
Name:
Baptist Memorial Hospital and Cancer Center-Desoto
Address:
City:
Southhaven
Zip:
38671
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
901-226-1366
Email:
BCCclintrials@bmhcc.org
Investigator:
Last name:
Salil Goorha
Email:
Principal Investigator
Facility:
Name:
Siteman Cancer Center at West County Hospital
Address:
City:
Creve Coeur
Zip:
63141
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-600-3606
Email:
info@siteman.wustl.edu
Investigator:
Last name:
Geoffrey L. Uy
Email:
Principal Investigator
Facility:
Name:
University Health Truman Medical Center
Address:
City:
Kansas City
Zip:
64108
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
816-404-4375
Investigator:
Last name:
Tara L. Lin
Email:
Principal Investigator
Facility:
Name:
University of Kansas Cancer Center - North
Address:
City:
Kansas City
Zip:
64154
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
913-588-3671
Email:
KUCC_Navigation@kumc.edu
Investigator:
Last name:
Tara L. Lin
Email:
Principal Investigator
Facility:
Name:
University of Kansas Cancer Center - Lee's Summit
Address:
City:
Lee's Summit
Zip:
64064
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
913-588-3671
Email:
KUCC_Navigation@kumc.edu
Investigator:
Last name:
Tara L. Lin
Email:
Principal Investigator
Facility:
Name:
Heartland Regional Medical Center
Address:
City:
Saint Joseph
Zip:
64506
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
816-271-7937
Email:
linda.schumacher@mymlc.com
Investigator:
Last name:
Jay W. Carlson
Email:
Principal Investigator
Facility:
Name:
Washington University School of Medicine
Address:
City:
Saint Louis
Zip:
63110
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-600-3606
Email:
info@siteman.wustl.edu
Investigator:
Last name:
Geoffrey L. Uy
Email:
Principal Investigator
Facility:
Name:
Siteman Cancer Center-South County
Address:
City:
Saint Louis
Zip:
63129
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-600-3606
Email:
info@siteman.wustl.edu
Investigator:
Last name:
Geoffrey L. Uy
Email:
Principal Investigator
Facility:
Name:
Siteman Cancer Center at Christian Hospital
Address:
City:
Saint Louis
Zip:
63136
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-600-3606
Email:
info@siteman.wustl.edu
Investigator:
Last name:
Geoffrey L. Uy
Email:
Principal Investigator
Facility:
Name:
Siteman Cancer Center at Saint Peters Hospital
Address:
City:
Saint Peters
Zip:
63376
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-600-3606
Email:
info@siteman.wustl.edu
Investigator:
Last name:
Geoffrey L. Uy
Email:
Principal Investigator
Facility:
Name:
Billings Clinic Cancer Center
Address:
City:
Billings
Zip:
59101
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-996-2663
Email:
research@billingsclinic.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Bozeman Health Deaconess Hospital
Address:
City:
Bozeman
Zip:
59715
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Benefis Sletten Cancer Institute
Address:
City:
Great Falls
Zip:
59405
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Logan Health Medical Center
Address:
City:
Kalispell
Zip:
59901
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Saint Patrick Hospital - Community Hospital
Address:
City:
Missoula
Zip:
59802
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-327-3118
Email:
amy.hanneman@providence.org
Investigator:
Last name:
Charles W. Drescher
Email:
Principal Investigator
Facility:
Name:
Community Medical Center
Address:
City:
Missoula
Zip:
59804
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
406-969-6060
Email:
mccinfo@mtcancer.org
Investigator:
Last name:
John M. Schallenkamp
Email:
Principal Investigator
Facility:
Name:
Nebraska Medicine-Bellevue
Address:
City:
Bellevue
Zip:
68123
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
402-559-6941
Email:
unmcrsa@unmc.edu
Investigator:
Last name:
Michael Haddadin
Email:
Principal Investigator
Facility:
Name:
Nebraska Medicine-Village Pointe
Address:
City:
Omaha
Zip:
68118
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
402-559-5600
Investigator:
Last name:
Michael Haddadin
Email:
Principal Investigator
Facility:
Name:
University of Nebraska Medical Center
Address:
City:
Omaha
Zip:
68198
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
402-559-6941
Email:
unmcrsa@unmc.edu
Investigator:
Last name:
Michael Haddadin
Email:
Principal Investigator
Facility:
Name:
OptumCare Cancer Care at Seven Hills
Address:
City:
Henderson
Zip:
89052
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
702-384-0013
Email:
research@sncrf.org
Investigator:
Last name:
John A. Ellerton
Email:
Principal Investigator
Facility:
Name:
OptumCare Cancer Care at Charleston
Address:
City:
Las Vegas
Zip:
89102
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
702-384-0013
Email:
research@sncrf.org
Investigator:
Last name:
John A. Ellerton
Email:
Principal Investigator
Facility:
Name:
OptumCare Cancer Care at Fort Apache
Address:
City:
Las Vegas
Zip:
89148
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
702-384-0013
Email:
research@sncrf.org
Investigator:
Last name:
John A. Ellerton
Email:
Principal Investigator
Facility:
Name:
Memorial Sloan Kettering Basking Ridge
Address:
City:
Basking Ridge
Zip:
07920
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
212-639-7592
Investigator:
Last name:
Aaron D. Goldberg
Email:
Principal Investigator
Facility:
Name:
Monmouth Medical Center
Address:
City:
Long Branch
Zip:
07740
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
732-923-6564
Email:
mary.danish@rwjbh.org
Investigator:
Last name:
Neil D. Palmisiano
Email:
Principal Investigator
Facility:
Name:
Memorial Sloan Kettering Monmouth
Address:
City:
Middletown
Zip:
07748
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
212-639-7592
Investigator:
Last name:
Aaron D. Goldberg
Email:
Principal Investigator
Facility:
Name:
Memorial Sloan Kettering Bergen
Address:
City:
Montvale
Zip:
07645
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
212-639-7592
Investigator:
Last name:
Aaron D. Goldberg
Email:
Principal Investigator
Facility:
Name:
Rutgers Cancer Institute of New Jersey
Address:
City:
New Brunswick
Zip:
08903
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
732-235-7356
Investigator:
Last name:
Neil D. Palmisiano
Email:
Principal Investigator
Facility:
Name:
Community Medical Center
Address:
City:
Toms River
Zip:
08755
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
732-557-8294
Email:
Lennette.Gonzales@rwjbh.org
Investigator:
Last name:
Neil D. Palmisiano
Email:
Principal Investigator
Facility:
Name:
University of New Mexico Cancer Center
Address:
City:
Albuquerque
Zip:
87106
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
505-925-0348
Email:
HSC-ClinicalTrialInfo@salud.unm.edu
Investigator:
Last name:
Charles Foucar
Email:
Principal Investigator
Facility:
Name:
Montefiore Medical Center - Moses Campus
Address:
City:
Bronx
Zip:
10467
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
718-379-6866
Email:
eskwak@montefiore.org
Investigator:
Last name:
Ioannis Mantzaris
Email:
Principal Investigator
Facility:
Name:
Memorial Sloan Kettering Commack
Address:
City:
Commack
Zip:
11725
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
212-639-7592
Investigator:
Last name:
Aaron D. Goldberg
Email:
Principal Investigator
Facility:
Name:
Mount Sinai Hospital
Address:
City:
New York
Zip:
10029
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
212-824-7309
Email:
CCTO@mssm.edu
Investigator:
Last name:
Douglas A. Tremblay
Email:
Principal Investigator
Facility:
Name:
Memorial Sloan Kettering Cancer Center
Address:
City:
New York
Zip:
10065
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
212-639-7592
Investigator:
Last name:
Aaron D. Goldberg
Email:
Principal Investigator
Facility:
Name:
University of Rochester
Address:
City:
Rochester
Zip:
14642
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
585-275-5830
Investigator:
Last name:
Paul M. Barr
Email:
Principal Investigator
Facility:
Name:
State University of New York Upstate Medical University
Address:
City:
Syracuse
Zip:
13210
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
315-464-5476
Investigator:
Last name:
Teresa C. Gentile
Email:
Principal Investigator
Facility:
Name:
Memorial Sloan Kettering Nassau
Address:
City:
Uniondale
Zip:
11553
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
212-639-7592
Investigator:
Last name:
Aaron D. Goldberg
Email:
Principal Investigator
Facility:
Name:
Duke University Medical Center
Address:
City:
Durham
Zip:
27710
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
888-275-3853
Investigator:
Last name:
Harry P. Erba
Email:
Principal Investigator
Facility:
Name:
Case Western Reserve University
Address:
City:
Cleveland
Zip:
44106
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-641-2422
Email:
CTUReferral@UHhospitals.org
Investigator:
Last name:
Benjamin K. Tomlinson
Email:
Principal Investigator
Facility:
Name:
University of Oklahoma Health Sciences Center
Address:
City:
Oklahoma City
Zip:
73104
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
405-271-8777
Email:
ou-clinical-trials@ouhsc.edu
Investigator:
Last name:
Manu Pandey
Email:
Principal Investigator
Facility:
Name:
Providence Newberg Medical Center
Address:
City:
Newberg
Zip:
97132
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
503-215-2614
Email:
CanRsrchStudies@providence.org
Investigator:
Last name:
Charles W. Drescher
Email:
Principal Investigator
Facility:
Name:
Providence Willamette Falls Medical Center
Address:
City:
Oregon City
Zip:
97045
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
503-215-2614
Email:
CanRsrchStudies@providence.org
Investigator:
Last name:
Charles W. Drescher
Email:
Principal Investigator
Facility:
Name:
Providence Portland Medical Center
Address:
City:
Portland
Zip:
97213
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
503-215-2614
Email:
CanRsrchStudies@providence.org
Investigator:
Last name:
Charles W. Drescher
Email:
Principal Investigator
Facility:
Name:
Providence Saint Vincent Medical Center
Address:
City:
Portland
Zip:
97225
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
503-215-2614
Email:
CanRsrchStudies@providence.org
Investigator:
Last name:
Charles W. Drescher
Email:
Principal Investigator
Facility:
Name:
Oregon Health and Science University
Address:
City:
Portland
Zip:
97239
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
503-494-1080
Email:
trials@ohsu.edu
Investigator:
Last name:
Curtis A. Lachowiez
Email:
Principal Investigator
Facility:
Name:
Geisinger Medical Center
Address:
City:
Danville
Zip:
17822
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
570-271-5251
Email:
HemonCCTrials@geisinger.edu
Investigator:
Last name:
Joseph J. Vadakara
Email:
Principal Investigator
Facility:
Name:
University of Pennsylvania/Abramson Cancer Center
Address:
City:
Philadelphia
Zip:
19104
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
855-216-0098
Email:
PennCancerTrials@careboxhealth.com
Investigator:
Last name:
Keith W. Pratz
Email:
Principal Investigator
Facility:
Name:
Thomas Jefferson University Hospital
Address:
City:
Philadelphia
Zip:
19107
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
215-600-9151
Email:
ONCTrialNow@jefferson.edu
Investigator:
Last name:
Margaret T. Kasner
Email:
Principal Investigator
Facility:
Name:
Reading Hospital
Address:
City:
West Reading
Zip:
19611
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
610-988-9323
Investigator:
Last name:
Terrence P. Cescon
Email:
Principal Investigator
Facility:
Name:
Prisma Health Cancer Institute - Spartanburg
Address:
City:
Boiling Springs
Zip:
29316
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
864-241-6251
Investigator:
Last name:
Suzanne R. Fanning
Email:
Principal Investigator
Facility:
Name:
Prisma Health Cancer Institute - Easley
Address:
City:
Easley
Zip:
29640
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
864-522-2066
Email:
Kim.Williams3@prismahealth.org
Investigator:
Last name:
Suzanne R. Fanning
Email:
Principal Investigator
Facility:
Name:
Prisma Health Cancer Institute - Butternut
Address:
City:
Greenville
Zip:
29605
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
864-241-6251
Investigator:
Last name:
Suzanne R. Fanning
Email:
Principal Investigator
Facility:
Name:
Prisma Health Cancer Institute - Faris
Address:
City:
Greenville
Zip:
29605
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
864-241-6251
Investigator:
Last name:
Suzanne R. Fanning
Email:
Principal Investigator
Facility:
Name:
Prisma Health Cancer Institute - Eastside
Address:
City:
Greenville
Zip:
29615
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
864-241-6251
Investigator:
Last name:
Suzanne R. Fanning
Email:
Principal Investigator
Facility:
Name:
Prisma Health Cancer Institute - Greer
Address:
City:
Greer
Zip:
29650
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
864-241-6251
Investigator:
Last name:
Suzanne R. Fanning
Email:
Principal Investigator
Facility:
Name:
Prisma Health Cancer Institute - Seneca
Address:
City:
Seneca
Zip:
29672
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
864-241-6251
Investigator:
Last name:
Suzanne R. Fanning
Email:
Principal Investigator
Facility:
Name:
Baptist Memorial Hospital and Cancer Center-Collierville
Address:
City:
Collierville
Zip:
38017
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
901-226-1366
Email:
BCCclintrials@bmhcc.org
Investigator:
Last name:
Salil Goorha
Email:
Principal Investigator
Facility:
Name:
Baptist Memorial Hospital and Cancer Center-Memphis
Address:
City:
Memphis
Zip:
38120
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
901-226-1366
Email:
BCCclintrials@bmhcc.org
Investigator:
Last name:
Salil Goorha
Email:
Principal Investigator
Facility:
Name:
University of Virginia Cancer Center
Address:
City:
Charlottesville
Zip:
22908
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
434-243-6303
Email:
uvacancertrials@hscmail.mcc.virginia.edu
Investigator:
Last name:
Daniel R. Reed
Email:
Principal Investigator
Facility:
Name:
Inova Schar Cancer Institute
Address:
City:
Fairfax
Zip:
22031
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
703-720-5210
Email:
Stephanie.VanBebber@inova.org
Investigator:
Last name:
Danielle A. Shafer
Email:
Principal Investigator
Facility:
Name:
Inova Fairfax Hospital
Address:
City:
Falls Church
Zip:
22042
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
703-208-6650
Email:
Stephanie.VanBebber@inova.org
Investigator:
Last name:
Danielle A. Shafer
Email:
Principal Investigator
Facility:
Name:
Virginia Commonwealth University/Massey Cancer Center
Address:
City:
Richmond
Zip:
23298
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Email:
CTOclinops@vcu.edu
Investigator:
Last name:
Keri R. Maher
Email:
Principal Investigator
Facility:
Name:
Duluth Clinic Ashland
Address:
City:
Ashland
Zip:
54806
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
218-786-3308
Email:
CancerTrials@EssentiaHealth.org
Investigator:
Last name:
Bret E. Friday
Email:
Principal Investigator
Facility:
Name:
Marshfield Medical Center-EC Cancer Center
Address:
City:
Eau Claire
Zip:
54701
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-782-8581
Email:
oncology.clinical.trials@marshfieldresearch.org
Investigator:
Last name:
Adedayo A. Onitilo
Email:
Principal Investigator
Facility:
Name:
Saint Vincent Hospital Cancer Center Green Bay
Address:
City:
Green Bay
Zip:
54301
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
920-433-8889
Email:
ewd_research_admin@hshs.org
Investigator:
Last name:
Matthew L. Ryan
Email:
Principal Investigator
Facility:
Name:
Saint Vincent Hospital Cancer Center at Saint Mary's
Address:
City:
Green Bay
Zip:
54303
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
920-433-8889
Email:
ewd_research_admin@hshs.org
Investigator:
Last name:
Matthew L. Ryan
Email:
Principal Investigator
Facility:
Name:
Gundersen Lutheran Medical Center
Address:
City:
La Crosse
Zip:
54601
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
608-775-2385
Email:
cancerctr@gundersenhealth.org
Investigator:
Last name:
David E. Marinier
Email:
Principal Investigator
Facility:
Name:
William S Middleton VA Medical Center
Address:
City:
Madison
Zip:
53705
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
608-256-1901
Phone ext:
17007
Investigator:
Last name:
Christopher D. Fletcher
Email:
Principal Investigator
Facility:
Name:
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
Address:
City:
Madison
Zip:
53718
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-622-8922
Email:
clinicaltrials@cancer.wisc.edu
Investigator:
Last name:
Kieran D. Sahasrabudhe
Email:
Principal Investigator
Facility:
Name:
University of Wisconsin Carbone Cancer Center - University Hospital
Address:
City:
Madison
Zip:
53792
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
800-622-8922
Email:
clinicaltrials@cancer.wisc.edu
Investigator:
Last name:
Kieran D. Sahasrabudhe
Email:
Principal Investigator
Facility:
Name:
Medical College of Wisconsin
Address:
City:
Milwaukee
Zip:
53226
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
414-805-3666
Investigator:
Last name:
Ehab L. Atallah
Email:
Principal Investigator
Facility:
Name:
ProHealth D N Greenwald Center
Address:
City:
Mukwonago
Zip:
53149
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Email:
research.institute@phci.org
Investigator:
Last name:
Timothy R. Wassenaar
Email:
Principal Investigator
Facility:
Name:
ProHealth Oconomowoc Memorial Hospital
Address:
City:
Oconomowoc
Zip:
53066
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
262-928-7878
Investigator:
Last name:
Timothy R. Wassenaar
Email:
Principal Investigator
Facility:
Name:
Saint Vincent Hospital Cancer Center at Oconto Falls
Address:
City:
Oconto Falls
Zip:
54154
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
920-433-8889
Email:
ewd_research_admin@hshs.org
Investigator:
Last name:
Matthew L. Ryan
Email:
Principal Investigator
Facility:
Name:
Saint Vincent Hospital Cancer Center at Sheboygan
Address:
City:
Sheboygan
Zip:
53081
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
920-433-8889
Email:
ewd_research_admin@hshs.org
Investigator:
Last name:
Matthew L. Ryan
Email:
Principal Investigator
Facility:
Name:
Saint Vincent Hospital Cancer Center at Sturgeon Bay
Address:
City:
Sturgeon Bay
Zip:
54235-1495
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
920-433-8889
Email:
ewd_research_admin@hshs.org
Investigator:
Last name:
Matthew L. Ryan
Email:
Principal Investigator
Facility:
Name:
ProHealth Waukesha Memorial Hospital
Address:
City:
Waukesha
Zip:
53188
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
262-928-7632
Investigator:
Last name:
Timothy R. Wassenaar
Email:
Principal Investigator
Facility:
Name:
UW Cancer Center at ProHealth Care
Address:
City:
Waukesha
Zip:
53188
Country:
United States
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
262-928-5539
Email:
Chanda.miller@phci.org
Investigator:
Last name:
Timothy R. Wassenaar
Email:
Principal Investigator
Facility:
Name:
Tom Baker Cancer Centre
Address:
City:
Calgary
Zip:
T2N 4N2
Country:
Canada
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
403-521-3433
Investigator:
Last name:
Mary L. Savoie
Email:
Principal Investigator
Facility:
Name:
Centro Comprensivo de Cancer de UPR
Address:
City:
San Juan
Zip:
00927
Country:
Puerto Rico
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
888-823-5923
Email:
ctsucontact@westat.com
Investigator:
Last name:
Luis J. Santos Reyes
Email:
Principal Investigator
Facility:
Name:
San Juan City Hospital
Address:
City:
San Juan
Zip:
00936
Country:
Puerto Rico
Status:
Recruiting
Contact:
Last name:
Site Public Contact
Phone:
787-763-1296
Investigator:
Last name:
Luis J. Santos Reyes
Email:
Principal Investigator
Start date:
June 18, 2024
Completion date:
May 15, 2029
Lead sponsor:
Agency:
National Cancer Institute (NCI)
Agency class:
NIH
Source:
National Cancer Institute (NCI)
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05564390
